"Man I'm gettin' too old for this sh!t."Alnylam's "Glover" patent has been overturned in Europe. Alnylam has their say here, Silence Therapeutics' slant is here.
We've often noted that with no RNAi therapies on the market and companies effectively operating under the research exemption granted via the 2005 Merck v Integra Supreme Court decision that it's difficult to weigh in on RNAi IP (we do however acknowledge that a good proxy for determining the eventual IP winner is watching where deal dollars wind up, and by that measure Alnylam is lightyears ahead).
So do we know what the European Patent Office decision means in the long run? No. Does it give us an opportunity to entertain you on a sunny summer Friday with Lethal Weapon references? Yes.
We've often noted that with no RNAi therapies on the market and companies effectively operating under the research exemption granted via the 2005 Merck v Integra Supreme Court decision that it's difficult to weigh in on RNAi IP (we do however acknowledge that a good proxy for determining the eventual IP winner is watching where deal dollars wind up, and by that measure Alnylam is lightyears ahead).
So do we know what the European Patent Office decision means in the long run? No. Does it give us an opportunity to entertain you on a sunny summer Friday with Lethal Weapon references? Yes.
